G1 is developing three new oncology therapies that are currently in clinical trials
G1 is advancing three clinical-stage programs, trilaciclib, lerociclib and G1T48, that are designed to improve patient outcomes for those affected by cancer. To learn more about our clinical trials, please visit www.clinicaltrials.gov or contact us at email@example.com.
Patients and families should speak to their physician about risks and benefits of a clinical trial and to ask whether a study is right for them.
Trilaciclib is a first-in-class investigational therapy designed to preserve bone marrow and immune system function during chemotherapy and improve patient outcomes. Trilaciclib is currently being studied in small cell lung cancer and triple-negative breast cancer. At this time, we have completed enrollment for our trilaciclib clinical trials and are not recruiting patients for our ongoing trials. Trials evaluating trilaciclib in additional tumor types will begin in 2020.
Lerociclib is a differentiated oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in types of breast and lung cancer. It is currently being studied in estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer and epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer. At this time, we have completed enrollment and are not recruiting patients for our ongoing trials. A pivotal trial of lerociclib in combination with fulvestrant in ER+, HER2- breast cancer is expected to begin in 2020.
G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) being studied as monotherapy or in combination with other targeted therapies to treat estrogen receptor-positive (ER+) breast cancer. We are currently recruiting women with ER+, HER2-negative advanced breast cancer for a Phase 1 open label trial assessing the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of G1T48. For more information, please visit www.clinicaltrials.gov (Identifier: NCT03455270).